FDC vs SUPRIYA: Stock Comparison

FDC Limited vs Supriya Lifescience Limited

Live data: 24 July 2026, 4:08 PM IST • Source: NSE and company filings

Supriya Lifescience Limited is the larger company by market capitalisation. FDC Limited shows a lower P/E and a higher dividend yield, while Supriya Lifescience Limited shows a higher ROE, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of FDC Limited and Supriya Lifescience Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, FDC is more favourable on 5 of 13 scored metrics and SUPRIYA on 8These counts are context-free and are not an overall rating.

Key Differences

Market Cap
SUPRIYA is the larger company
₹6,771 Cr vs ₹6,606 Cr
P/E Ratio
FDC has a lower P/E
23.92x vs 32.42x
P/B Ratio
FDC has a lower P/B
2.71x vs 5.66x
EPS
SUPRIYA has higher earnings per share
₹25.94 vs ₹17.27
Dividend Yield
FDC has a higher dividend yield
2.42% vs 0.11%
Revenue Growth (TTM YoY)
SUPRIYA has faster revenue growth
50.2% vs 18.9%
EPS Growth (TTM YoY)
FDC has faster EPS growth
166.8% vs 46.7%
Qtr Sales Growth
SUPRIYA has stronger quarterly sales growth
50.2% vs 18.9%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricFDCSUPRIYA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricFDCSUPRIYA
Live Price₹412.95₹840.5
Day Change2.92%0.91%
Volume96,7781.12 L
52-Week High₹527.8₹1,085
52-Week Low₹312.95₹545.5
Distance from 52W High-21.76%-22.53%

Valuation

MetricFDCSUPRIYA
Market Cap₹6,606 Cr₹6,771 Cr
P/E Ratio23.92x32.42x
P/B Ratio2.71x5.66x
EPS₹17.27₹25.94
Book Value₹152.62₹148.77
Dividend Yield2.42%0.11%

Growth

MetricFDCSUPRIYA
Revenue Growth (TTM YoY)18.9%50.2%
EPS Growth (TTM YoY)166.8%46.7%
Qtr Sales Growth18.9%50.2%
Qtr Profit Growth167%47.3%

Profitability & Leverage

MetricFDCSUPRIYA
ROE12.5%19.1%
ROCE16.7%25.1%
Net Margin12.96%25.26%
Operating Margin15.9%35.5%
Debt to Equity0.01x0x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricFDCSUPRIYA
Promoter Holding69.66%68.3%
FII Holding1.4% 1 pp6.19% 1.03 pp
DII Holding6.31% 0.02 pp5.3% 0.4 pp
Public Holding22.63% 0.98 pp20.21% 0.63 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: FDC Limited and Supriya Lifescience Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.